Articles Archive - Page 190 of 814

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

Michele B. Kaufman, PharmD, BCGP | August 4, 2020

In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…

The ACR Expresses Strong Support for Dr. Anthony Fauci

From the College | July 29, 2020

The ACR, on behalf of its more than 7,700 members of the professional rheumatology community, wishes to express strong support for Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic. During…

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill | July 29, 2020

ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…

Insights into Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

Lara C. Pullen, PhD | July 29, 2020

Recent research found inflammatory arthritis caused by immune checkpoint inhibitors (ICIs) may become a long-term disease, requiring rheumatology care and immunomodulatory treatment. Some patients experience active inflammatory arthritis years after ICI cessation…

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks | July 27, 2020

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…

Lenabasum for Diffuse Cutaneous Systemic Sclerosis

Arthritis & Rheumatology | July 27, 2020

In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…

How to Empower Lupus Patients Through Social Media & Online Resources

Carina Stanton | July 27, 2020

Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…

ACR Updates COVID-19 Clinical Guidance for Adult Patients

From the College | July 21, 2020

Note: This article was updated July 21 to add recommendations on restarting biologics following COVID-19. On April 29, the ACR released Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic and later updated the guidance for publication in Arthritis & Rheumatology. The recommendations address various treatment options and provide general…

Financial Impacts of COVID-19 on Practices: Q&A with Norman Gaylis, MD

Kimberly Retzlaff | July 17, 2020

Community rheumatology practices are confronting a significant financial fallout from stay-at-home orders and fears that keep patients at home, as well as reimbursement challenges.

RheumPAC Supports Rheumatology Through the Pandemic

Kurt Ullman | July 17, 2020

With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.